» Articles » PMID: 37397144

Extracellular Vesicles: Pathogenic Messengers and Potential Therapy for Neonatal Lung Diseases

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2023 Jul 3
PMID 37397144
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular vesicles (EVs) are a heterogeneous group of nano-sized membranous structures increasingly recognized as mediators of intercellular and inter-organ communication. EVs contain a cargo of proteins, lipids and nucleic acids, and their cargo composition is highly dependent on the biological function of the parental cells. Their cargo is protected from the extracellular environment by the phospholipid membrane, thus allowing for safe transport and delivery of their intact cargo to nearby or distant target cells, resulting in modification of the target cell's gene expression, signaling pathways and overall function. The highly selective, sophisticated network through which EVs facilitate cell signaling and modulate cellular processes make studying EVs a major focus of interest in understanding various biological functions and mechanisms of disease. Tracheal aspirate EV-miRNA profiling has been suggested as a potential biomarker for respiratory outcome in preterm infants and there is strong preclinical evidence showing that EVs released from stem cells protect the developing lung from the deleterious effects of hyperoxia and infection. This article will review the role of EVs as pathogenic messengers, biomarkers, and potential therapies for neonatal lung diseases.

Citing Articles

Extracellular vesicles and preterm infant diseases.

Chen W, Kongsomros S, Thorman A, Esfandiari L, Morrow A, Chutipongtanate S Front Pediatr. 2025; 13:1550115.

PMID: 40034714 PMC: 11873092. DOI: 10.3389/fped.2025.1550115.


Unveiling the Emerging Role of Extracellular Vesicle-Inflammasomes in Hyperoxia-Induced Neonatal Lung and Brain Injury.

Young K, Benny M, Schmidt A, Wu S Cells. 2025; 13(24.

PMID: 39768185 PMC: 11674922. DOI: 10.3390/cells13242094.

References
1.
Porzionato A, Zaramella P, Dedja A, Guidolin D, Van Wemmel K, Macchi V . Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2018; 316(1):L6-L19. DOI: 10.1152/ajplung.00109.2018. View

2.
Genschmer K, Russell D, Lal C, Szul T, Bratcher P, Noerager B . Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. Cell. 2019; 176(1-2):113-126.e15. PMC: 6368091. DOI: 10.1016/j.cell.2018.12.002. View

3.
Kubo H . Extracellular Vesicles in Lung Disease. Chest. 2017; 153(1):210-216. DOI: 10.1016/j.chest.2017.06.026. View

4.
Martinez-Greene J, Hernandez-Ortega K, Quiroz-Baez R, Resendis-Antonio O, Pichardo-Casas I, Sinclair D . Quantitative proteomic analysis of extracellular vesicle subgroups isolated by an optimized method combining polymer-based precipitation and size exclusion chromatography. J Extracell Vesicles. 2021; 10(6):e12087. PMC: 8077108. DOI: 10.1002/jev2.12087. View

5.
Wang J, Zhang A, Huang F, Xu J, Zhao M . MSC-EXO and tempol ameliorate bronchopulmonary dysplasia in newborn rats by activating HIF-1α. Pediatr Pulmonol. 2023; 58(5):1367-1379. DOI: 10.1002/ppul.26317. View